Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120502 | 1.00 | SCD5 (0.47) | SCD5PDE1CUSP30PDE4BHDAC4 | |
| SCHEMBL29849392 | 0.91 | PDE1C (0.47) | SCD5PDE1CUSP30PDE4BHDAC4 | |
| SCHEMBL21385205 | 0.91 | PDE1C (0.47) | SCD5PDE1CUSP30PDE4BHDAC4 | |
| SCHEMBL21384715 | 0.83 | SCD5 (0.54) | SCD5PDE1CPDE4BHDAC4FASN | |
| SCHEMBL30112308 | 0.82 | JAK2 (0.43) | PDE1CUSP30PDE4BLRRK2GPR119 | |
| SCHEMBL29197746 | 0.82 | JAK2 (0.43) | PDE1CUSP30PDE4BLRRK2GPR119 | |
| SCHEMBL29197744 | 0.82 | JAK2 (0.43) | PDE1CUSP30PDE4BLRRK2GPR119 | |
| SCHEMBL29196983 | 0.81 | PDE4B (0.44) | USP30PDE4BSLC34A1NAMPTRORC | |
| SCHEMBL30732296 | 0.80 | PDE1C (0.41) | PDE1CPDE4BHDAC4GPR119FASN | |
| SCHEMBL23211951 | 0.80 | GPR119 (0.51) | PDE1CPDE4BNAMPTGPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SCD5 162/4885PDE1C 2712/4885USP30 385/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SCD5 162/4885PDE1C 2712/4885USP30 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.